Introduction
The primary goals of antiepileptic drug (AED) treatment are to achieve complete seizure freedom, ideally without adverse events, reduce morbidity, mortality, and seizure-related accidents, and improve quality of life. 1 In two-thirds of the patients with epilepsy these goals are feasible with optimum AED therapy. For the remaining one-third of patients with refractory epilepsies these goals are not reached with existing AEDs and, the introduction of several new AEDs in the recent past might be a welcome development for improved patient treatment. Some studies 2, 3 have shown results of treatment changes in an apparent refractory population.
With a growing number of AEDs, it becomes more difficult for clinicians to make a rational choice which drug to prescribe for which patient. To date, treatment of epilepsy is rather more empirical than evidence-based. 1 In an ideal situation, treatment guidelines will use information from large multicentre randomized controlled trials that compare AEDs in a head to head fashion. These trials are however rarely performed. In the absence of such trials, other methods must be used to compare new AEDs on their intrinsic properties. The relevance of findings derived from metaanalyses to clinical practice is limited. Studies included in metaanalyses are typically of short duration among other limitations, 4 whereas epilepsy is a chronic condition. Therefore, long-term open label observational studies and clinical practice audits better reflect everyday clinical practice regarding long-term efficacy and safety issues. 5 One way to compare the long-term performances of AEDs in clinical practice is to evaluate retention rates. Prolonged retention of patients on their AED therapy is now accepted as one of the clearest reflections of therapeutic efficiency and represents a Lamotrigine Levetiracetam Topiramate Long-term retention Side-effects of AEDs Antiepileptics Cognitive function
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Objective: To determine long-term retention, percentage of patients withdrawing because of adverse events, percentage of patients achieving seizure freedom, safety profile of the new anti-epileptic drugs lamotrigine, levetiracetam and topiramate. Methods: All patients treated with lamotrigine, levetiracetam or topiramate in the Epilepsy Centre were identified. Each drug was analyzed from introduction of the drug in the Netherlands up to a final assessment point 2 years later. Results: Data from 1066 patients were included: 336 for lamotrigine, 301 for levetiracetam, 429 for topiramate. Two-year retention rates were 69.2% (lamotrigine), 45.8% (levetiracetam), 38.3% (topiramate); (LTG vs. LEV at p < 0.001; LTG vs. TPM at p < 0.001; LEV vs. TPM at p = 0.005). Seizure freedom rates were lowest for lamotrigine and highest for levetiracetam. Adverse events played a role in drug discontinuation in 154/429 patients (35.9%) on topiramate, 52/336 patients (15.5%) on lamotrigine (p < 0.001), 68/301 patients (22.5%) on levetiracetam (p < 0.001). Mood and general CNS-effects are common in patients on lamotrigine and levetiracetam, and neurocognitive side effects are most prevalent in patients on topiramate. A positive effect on cognition is frequently noted in patients on lamotrigine. Conclusion: A drug that is only modestly efficacious but has a favourable safety profile may look better than a drug that is more efficacious but produces clinically meaningful adverse events. Therefore, a drug's retention rate is mainly determined by its side effect profile. As a consequence, retention rate was highest for lamotrigine and lowest for topiramate. Intermediate retention rates were seen with levetiracetam use.
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clinically meaningful composite measure of both efficacy and safety over time. 6 Retention-time studies are especially useful when the actual seizure-frequency reduction per patient and the percentage of seizure-free patients are determined. 7 Presently, it is not clear whether efficacy and safety contribute equally to the retention rate of new AEDs. One study mentions that retention rate may reflect more of AED tolerability rather than efficacy. 8 This audit focuses on the three most commonly prescribed new AEDs in patients with refractory epilepsies in a tertiary referral centre for epilepsy: lamotrigine (LTG), levetiracetam (LEV) and topiramate (TPM). Our objectives were to compare the long-term retention, the percentage of patients withdrawing because of adverse events, the percentage of patients achieving seizure freedom, and the safety profile of LTG, LEV and TPM.
Methods
The study was approved by the Institutional Medical Ethics Committee. All in-and out-patients who had been treated with LTG, LEV or TPM in a certain period in the Epilepsy Centre Kempenhaeghe were identified by means of our automated medical information system (MIS) and subsequently analyzed. Each drug was analyzed from the introduction of the drug in the Netherlands up to a final assessment point (TPM 1993 (TPM -2002 LTG 1996 LTG -1997 LEV 2001 LEV -2003 . Patients who had the drug of interest prescribed initially elsewhere were not included to avoid survival bias. Retention times were calculated from the time the patients started to take the drug of interest to the time they discontinued treatment, with a maximum follow-up period of 24 months. Data from patients who were still taking the drug at the time of data collection were counted as censored data.
A standardized data form was developed. The data were obtained from our Medical Information System and individual patient medical records. Epilepsy and seizures were classified using the International League Against Epilepsy (ILAE) classification. Treatment was evaluated every 6 months for each drug. Mood disorders due to the use of AEDs were classified into activating and sedating effects, with the former leading to aggression, hyperirritability, and agitation, and the latter leading to apathy and depression. 9, 10 Data forms were entered into a computerized database for analysis. Statistical analysis was performed using SPSS 15.0 for Windows. Retention rates were calculated by using Kaplan-Meier survival analysis, 11 and comparisons between the retention curves were analyzed using log-rank tests. Other comparisons between the drugs were analyzed using nonparametric statistics, Pearson X 2 .
Results
One hundred of 1166 patients had the drug of interest prescribed initially elsewhere or data were lacking. Therefore, data from 1066 patients were included in the analysis: 429 for TPM, 336 for LTG, and 301 for LEV. The main characteristics of patients are given in Table 1 . Populations representing LTG, LEV, and TPM were similar for the most important demographic and clinical variables and represent the typical group of refractory patients referred to a tertiary epilepsy centre.
Kaplan-Meier survival analysis, shown by Fig. 1 , revealed significant differences between the drugs. Estimated retention rates of 75.2% (LTG), 65.6% (LEV), and 51.7% (TPM) were reported at 1 year (LTG vs. LEV at p = 0.008; LTG vs. TPM at p < 0.001; LEV vs. TPM at p = 0.002). Retention at 2 years had decreased to 69.2% for LTG, 45.8% for LEV, and 38.3% for TPM (LTG vs. LEV at p < 0.001; LTG vs. TPM at p < 0.001; LEV vs. TPM at p = 0.005). Fig. 2 shows the percentages of patients that are free of seizures from baseline. Seizure freedom rates were lowest for LTG and highest for LEV at all assessment points. No statistically significant differences between the seizure freedom rates could be identified. Adverse events played a role in drug discontinuation in 154 of 429 patients (35.9%) on TPM (Fig. 3) . Significantly less patients discontinued drug treatment because of adverse events in the other populations: 52 of 336 patients (15.5%) on LTG (p < 0.001) and 68 of 301 patients (22.5%) on LEV (p < 0.001). The difference between LTG and LEV is also significant (p = 0.028).
The most frequently reported side effects in patients who discontinued treatment are listed in Table 2 . Effects on mood and general CNS-effects (dizziness, tiredness, sleepiness) were common side effects at time of discontinuation in patients on LTG, LEV, and TPM. In patients on TPM, the neurocognitive side effects like mental slowing and dysphasia were most important and contributed to almost half of patients in discontinuing treatment. Rash played a role in drug discontinuation in both the LTG and TPM study populations.
The most frequently reported side effects per assessment point are shown in Table 3 . Similarly, effects on mood and general CNSeffects are common side effects in patients on LTG and LEV, and neurocognitive side effects are most prevalent in patients on TPM. A positive effect on behaviour is most frequently noted in patients on LTG. Improved alertness, emotional stability, and reduced irritability were frequently noted. This effect is seen in a substantial number of patients on LEV only in the first 6 months, and not at all in patients on TPM.
Discussion
This audit compared the use of LTG, LEV, and TPM, presently three of the most commonly prescribed new AEDs in chronic epilepsy. The study population consisted of patients with chronic refractory epilepsy referred to a single tertiary epilepsy centre. The added value of this study is due to the direct comparison of the long-term performance of LTG, LEV, and TPM including seizure freedom rates and safety issues, the large number of patients included (n = 336 for LTG; n = 301 for LEV; n = 429 for TPM), the long period of evaluation (24 months), and the low risk of selection bias by the inclusion of all patients who were started on LTG, LEV, or TPM in a certain period. This is illustrated by the characteristics of our study population, specifically by a wide age range and a large number of children (22%) and mentally retarded (33%). The patients on each drug did not differ on any of the clinical or demographical variables, which allows us to compare LTG, LEV, and TPM and to assume that differences in outcome are drugrelated.
Many studies have been done on individual new AEDs as addon treatment. However, few compare these new AEDs with each other. Ideally, neurologists make treatment decisions based on results from long-term randomized controlled trials that make head-to-head comparisons. These trials are rarely performed because of specific reasons. 12 Therefore, results from long-term observational studies become increasingly more important, since these studies give clinicians insight in the long-term performance of new AEDs in terms of retention rate, seizure control, and safety profile. One way to compare the long-term performance of new AEDs in observational studies is to evaluate retention rates. Retention rate is considered to be a composite measure of drug efficacy and drug safety and expresses the willingness of patients to continue drug treatment. Therefore, it is clinically the most relevant parameter of an AED. In our study, retention rate at 2 years was highest with LTG (69.2%), followed by LEV (45.8%), and TPM (38.3%). Chung et al.
showed similar 2-year retention rates of 74.1% for LTG, 53.6% for LEV, and 44.2% for TPM (5) . In addition, a study executed in a residential community of adults with chronic epilepsy and learning disability found a higher retention rate at 5 years in patients on LTG (52%) compared to patients on LEV (32%) and TPM (28%). However, 2-year retention rates for LTG and LEV were similar (57% and 56%, respectively). 13 Contrary to those studies and most other published follow-up studies, we obtained estimates of the proportion of patients with complete seizure control for at least 6 months. This is relevant, since these figures provide clinically the most meaningful data for predicting the long-term efficacy of an AED.
14 This is especially important since in this study the category of patients were regarded as drug resistant and the new AEDs have substantially added value in this population. Surprisingly, higher seizure freedom rates were not associated with higher retention rates. Retention rate for LTG was highest, whereas seizure freedom rates, although not statistically significant, were lowest. Longterm retention for TPM was dramatically lower than for LTG, whereas seizure freedom rates were higher. This suggests that the impact of the achievement of seizure remission on long-term retention is considered less important. Moreover, it should be noted that not all patients who continue on therapy do so because of improvement in seizure frequency. Some patients continued drug treatment while experiencing even a higher seizure frequency.
As a marker of tolerability we used the percentage of patients withdrawing drug treatment because of adverse events. TPM was by far the least well-tolerated drug, followed by LEV, and LTG. AEDspecific adverse events that often led to discontinuation of drug treatment were mental slowing and dysphasia in patients on TPM, mood disorders in patients on LEV, and rash in patients on LTG, as previously reported in other studies. 8, 13, [15] [16] [17] [18] As expected, we found a correlation between side effects and long-term retention: the higher the percentages of patients withdrawing because of adverse events, the lower the retention rate. Several findings with respect to retention rates were noteworthy in our study. Firstly, retention rates could have been influenced by the sequence in which LTG, LEV, and TPM were marketed. Patients on drugs that were marketed first could have been withdrawn from treatment because of the availability of a new AED. On the other hand, drugs that were marketed later could have been tested in a more refractory population.
Secondly, if patients did stop taking the audit drug, they were most likely to do this in the first 6-12 months, mostly due to adverse events. This implicates that surviving the toxic effects of an AED in the early stage is a good indicator of long-term retention. This is also mentioned by other studies reporting continuation rates of about 90% for LTG, LEV, and TPM after surviving the initial stage of AED introduction. 8, 19 Thirdly, cognitive impairment is a common side effect in patients using AEDs. 20 Across studies, LTG adjunctive therapy did not worsen, and sometimes improved, pre-existing cognitive dysfunction in patients with epilepsy. 21 In one study, only 11 of 81 patients (13.6%) achieved a 50% reduction in seizure frequency on LTG, whereas more than 50% chose to continue LTG therapy, indicating that other factors influenced their decision. 22 In contrast, TPM has been associated with cognitive impairment, particularly in verbal function, memory, and attention in patients with epilepsy. 15, 23, 24 In our study, almost half of patients on TPM discontinued treatment because of the drug's negative effects on cognition. However, patients on LTG frequently experienced a positive effect on cognition. Patients were less irritable, more alert, and emotionally stable. We think that the side effect profile, and especially the impact of an AED on cognitive function, is the main determinant of retention rate. Therefore, effects on cognition constitute a key consideration in selecting antiepileptic drugs.
To conclude: the new AEDs have substantially added value in the group of drug resistant epilepsy patients. In addition a drug that is only modestly efficacious but has a favourable safety profile may seem better than a drug that is more efficacious but produces clinically meaningful adverse events. Therefore, a drug's retention rate is mainly determined by its side effect profile. The gain in quality of life after drug initiation determines the continuation rate of an individual AED, with the effects on cognition being far more important than seizure control. As a consequence, retention rate was highest for LTG and lowest for TPM. Intermediate retention rates were seen with LEV use. 
